Browse by Hotbed/Location
Filter News
Found 695,691 articles
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
Sponsored: Inspirational Space Sparks Scientific Innovation at the First Life Sciences Building i...
3/21/2023
Real estate development firm Sterling Bay launches life sciences division starting with Lincoln Yards, a 320,000 square foot site on the Chicago River. -
Enzo Biochem Reports Second Quarter Fiscal Year 2023 Financial Results
3/21/2023
Enzo Biochem, Inc. (NYSE:ENZ), a pioneering biosciences and diagnostics company, filed its Form 10-Q for the second quarter ended January 31, 2023 of Fiscal Year 2023.
-
Alveo Technologies Announces ISO 13485:2016 Certification
3/21/2023
Alveo Technologies, Inc. today announced its quality management system (QMS) has achieved ISO 13485:2016 certification for the design, development and manufacture of in vitro diagnostic kits and analyzers for the detection of infectious disease.
-
Lumicell Submits New Drug Application for LUMISIGHT™ Optical Imaging Agent to U.S. FDA for Intraoperative Breast Cancer Detection and Removal
3/21/2023
Lumicell, Inc. today announced a New Drug Application (NDA) for its LUMISIGHT™ Optical Imaging Agent has been submitted to the U.S. Food and Drug Administration (FDA).
-
Xentria Announces Peer Reviewed Publication of Biosimulation Model in Frontiers in Pharmacology Journal
3/21/2023
Xentria Announces Peer Reviewed Publication of Biosimulation Model in Frontiers in Pharmacology Journal.
-
Wugen Announces CEO Transition
3/21/2023
Wugen, Inc. today announced that Kumar Srinivasan Ph.D., M.B.A., has been appointed President and Chief Executive Officer, effective March 13, 2023.
-
Enable Biosciences Announces Relaunch of Website for Early Detection of Type 1 Diabetes
3/21/2023
Enable Biosciences, a biotechnology company dedicated to developing innovative diagnostics, announced the relaunch of its website, type1testing.enablebiosciences.com , which offers an at-home testing kit for the early detection of type 1 diabetes.
-
Evofem Biosciences Announces Cost Reduction Measures
3/21/2023
Evofem Biosciences, Inc. , (OTCQB: EVFM) (the "Company") today announced it has implemented measures to lower its operating expenses, with the goal of reaching cash flow break even by year-end 2023.
-
Scilex Holding Company Announces Financing of up to $25 Million to Enhance Commercialization of Three FDA Approved Non-Opioid Pain Management Products
3/21/2023
Scilex Holding Company announced that it has entered into a securities purchase agreement with YA II PN, Ltd., a Cayman Islands exempt limited partnership managed by Yorkville Advisors Global, LP (”Yorkville”), for the issuance and sale of unsecured convertible debentures in the principal amount of up to $25 million.
-
Adial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use Disorder
3/21/2023
Adial Pharmaceuticals, Inc. today announced it has engaged The Keswick Group, LLC, a biotech strategic commercial and business development advisory firm, to advance the Company’s partnering activities.
-
PREVISE CLOSES $3M SEED TO TACKLE EARLY CANCER DETECTION AND LAUNCHES COMPANY'S FIRST ESOPHAGEAL CANCER PROGNOSTIC TEST
3/21/2023
Previse, formerly known as Capsulomics, Inc., announced that the company has closed a $3M seed round and launched its first laboratory-developed test, Esopredict™.
-
Protalix BioTherapeutics Announces First Patient Dosed in First in Human Phase I Clinical Trial of PRX-115 for the Treatment of Severe Gout
3/21/2023
Protalix BioTherapeutics, Inc. today announced that the first patient has been dosed in the Company's phase I First in Human (FIH) clinical trial of PRX-115, the Company's recombinant PEGylated uricase product candidate under development as a potential treatment of severe gout.
-
Decibel Therapeutics Appoints Matthew Kapusta to its Board of Directors
3/21/2023
Decibel Therapeutics today announced the appointment of Matthew Kapusta to its Board of Directors.
-
Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial
3/21/2023
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company (the “Company”), today announced topline results from a Week 24 interim analysis of 160 subjects in its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide along with the results of the 12-week Phase 1b safety trial of pemvidutide in subjects with obesity or overweight and type 2 diabetes.
-
Algernon Pharmaceuticals Announces Launch of Rights Offering
3/21/2023
Algernon Pharmaceuticals Inc. announces it is undertaking a rights offering to raise gross proceeds of approximately $2,416,747 (the “Rights Offering”).
-
Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023
3/21/2023
Numinus Wellness Inc. today announced that Reid Robison, Chief Clinical Officer of Numinus, has contributed to studies published in four peer-reviewed papers thus far in 2023 for his work in the treatment of mental health disorders including Post-Traumatic Stress Disorder (PTSD), depression, and anxiety.
-
Brainomix Receives FDA Clearance for Its Flagship Stroke AI Imaging Software
3/21/2023
Brainomix today announced that its Brainomix 360 e-ASPECTS tool for stroke has received FDA clearance, enabling the Oxford-based company to deploy its cutting-edge stroke AI imaging platform to US stroke centers.
-
Coya Therapeutics, Inc. Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)
3/21/2023
Coya Therapeutics, Inc. today reported 48-week clinical data for its proof-of-concept open-label study in 4 ALS patients indicating that treatment with COYA 302 appeared to ameliorate disease progression.